• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Atrion Corporation

    5/30/24 9:28:36 AM ET
    $ATRI
    Medical/Dental Instruments
    Health Care
    Get the next $ATRI alert in real time by email
    SC 13D 1 d835225dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

     

    ATRION CORPORATION

    (Name of Issuer)

    COMMON STOCK, $0.10 PAR VALUE PER SHARE

    (Title of Class of Securities)

    049904105

    (CUSIP Number)

    Jennifer McDonough

    Executive Vice President,

    General Counsel and Secretary

    Nordson Corporation

    28601 Clemens Road

    Westlake, Ohio 44145

    with a copy to:

    James Dougherty

    Shanu Bajaj

    Davis Polk & Wardwell LLP

    450 Lexington Avenue

    New York, NY 10017

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 28, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format will include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page will be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page will not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but will be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     (1)    

     Names of reporting persons

     

     Nordson Corporation

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds (see instructions)

     

     OO

     (5)  

     Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     (6)  

     Citizenship or place of organization

     

     Ohio

    Number of

    shares  beneficially 

    owned by

    each

    reporting

    person

    with

     

        (7)     

     Sole voting power

     

     0 (See Item 5)

        (8)   

     Shared voting power

     

     386,910* (See Item 5)

        (9)   

     Sole dispositive power

     

     0 (See Item 5)

      

    (10)

      

     Shared dispositive power

     

     0 (See Item 5)

    (11)    

     Aggregate amount beneficially owned by each reporting person

     

     386,910*

    (12)  

     Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

     ☐

    (13)  

     Percent of class represented by amount in Row (11)

     

     22%*

    (14)  

     Type of reporting person (see instructions)

     

     CO  

     

    *

    As more fully described in the responses to Items 3 through 6 of this Schedule 13D, pursuant to the Voting Agreements (as defined in Item 3), based on 1,759,954 shares of Common Stock outstanding as of May 23, 2024, as reported by Issuer in the Merger Agreement (as defined below), which is attached hereto as Exhibit 99.1, the Reporting Person may be deemed to have beneficial ownership of 386,910 shares of Common Stock, which is equal to approximately 22% of the voting power of issued and outstanding shares of Common Stock as of May 23, 2024. Neither the filing of this Schedule 13D nor any of its contents will be deemed to constitute an admission by Nordson Corporation that it is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) or 13(g) of the Securities Exchange Act or for any other purpose, and such beneficial ownership is expressly disclaimed.


    Schedule 13D

    Item 1. Security and Issuer

    This Schedule 13D (this “Schedule 13D”) relates to shares of common stock, par value $0.10 per share (the “Common Stock”), of Atrion Corporation, a Delaware corporation (“Issuer”). Issuer’s principal executive offices are located at One Allentown Parkway, Allen, TX 75002.

    Item 2. Identity and Background

    This Schedule 13D is being filed by Nordson Corporation, an Ohio corporation (“Nordson”), with a principal business address of 28601 Clemens Road Westlake, OH 44145 (the “Reporting Person”).

    The principal business of Nordson is engineering, manufacturing and marketing differentiated products and systems used for precision dispensing, applying and controlling of adhesives, coatings, polymers, sealants, biomaterials, and other fluids, to test and inspect for quality, and to treat and cure surfaces and various medical products such as catheters, cannulas, medical balloons and medical tubing. Alpha Medical Merger Sub, Inc. (“Merger Sub”) is a wholly owned subsidiary of Nordson and was recently incorporated for the purpose of the Merger (as defined below) upon the terms and subject to the conditions set forth in the Merger Agreement (as defined below).

    Set forth on Annex A to this Schedule 13D, and incorporated herein by reference, is a list of the executive officers and directors of the Reporting Person (the “Scheduled Persons”) that contains the following information with respect to each such person: (a) name, (b) business address, (c) present principal occupation or employment (including the name and the principal business address, if other than Nordson, of any corporation or other organization in which such employment is conducted), and (d) citizenship. Except as set forth otherwise on Annex A, each person identified on Annex A is a citizen of the United States.

    During the last five years, neither the Reporting Person, nor, to the best of their knowledge, any of the Scheduled Persons, has been (i) convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 3. Source and Amount of Funds or other Consideration

    Items 4 and 5 are incorporated by reference in this Item 3 as if fully set forth herein.

    Pursuant to, and subject to the terms and conditions contained in, the Voting Agreements described in Item 4 of this statement, the Reporting Person may be deemed to have acquired beneficial ownership of the Subject Shares (as defined below) by virtue of the execution of the Voting Agreements (as defined in Item 4 below) by Nordson and with certain shareholders named on Annex B hereto (each, a “Voting Party” and together the “Voting Parties”).

    The shares of Common Stock beneficially owned by the Voting Parties have not been purchased by the Reporting Person, and thus no payments were made by or on behalf of the Reporting Person in connection with the execution of the Merger Agreement (as defined in Item 4 below) or the execution of the Voting Agreements. The Voting Parties will receive the same consideration per share of Common Stock as other shareholders receive pursuant to the terms of the Merger Agreement.

    Item 4. Purpose of Transaction

    Items 3 and 5 are incorporated by reference in this Item 4 as if fully set forth herein.

    Merger Agreement

    On May 28, 2024, Nordson, Issuer and Merger Sub entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other things, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Issuer (the “Merger”), with Issuer surviving the Merger as a wholly owned subsidiary of Nordson.


    Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of Common Stock (other than shares of Common Stock (i) held in the treasury of Issuer or owned by any direct or indirect wholly owned subsidiary of Issuer immediately prior to the Effective Time, (ii) owned by Merger Sub, Nordson or any direct or indirect wholly owned subsidiary of Nordson immediately prior to the Effective Time, or (iii) held by a holder or beneficial holder that or who is entitled to demand and has properly demanded appraisal for such shares of Common Stock in accordance with, and that or who complies in all respects with, Section 262 of the General Corporation Law of the State of Delaware) will be canceled and converted into the right to receive an amount in cash equal to $460.00 per share of Common Stock, without interest (the “Merger Consideration”).

    In addition, each restricted stock unit, whether stock-settled or cash-settled, and whether settled on a current or a deferred basis (each, a “Company RSU”) (including Company RSUs subject to market-or performance-based conditions (“Company PSUs”)), granted to an employee or non-employee service provider that is outstanding as of immediately prior to the Effective Time, whether vested but unsettled or unvested, will be canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of Common Stock underlying or denominated by such Company RSU (with respect to Company PSUs, vesting at target), less applicable taxes and authorized deductions.

    The consummation of the Merger (the “Closing”) is subject to the satisfaction or waiver of certain customary mutual conditions, including (i) the absence of any decision, injunction, decree, ruling, law or order (whether temporary, preliminary or permanent) issued by a governmental body of competent jurisdiction that is in effect and enjoins or otherwise prohibits or makes illegal the consummation of the Merger, (ii) the affirmative vote of the holders of a majority of all outstanding shares of Common Stock to adopt the Merger Agreement (the “Issuer Stockholder Approval”), (iii) the expiration or termination of any waiting period (and any extension thereof) applicable to the consummation of the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and under any agreement with a governmental body not to consummate the Merger, in Nordson’s case, without the imposition of any Burdensome Condition (as defined below), and (iv) the receipt of certain regulatory consents, approvals and authorizations under applicable antitrust and foreign direct investment laws and regulations in Turkey and Italy (the “Required Approvals”), in Nordson’s case, without the imposition of any Burdensome Condition (as defined below). A “Burdensome Condition” includes any action that would require Nordson or Merger Sub to (i) propose, negotiate, commit to or effect, by consent decree, hold separate orders or otherwise, the sale, divestiture, disposition, license or other conveyance of any categories, portions or parts of assets, properties, products, rights, services, or businesses of Nordson, Atrion or any of their respective affiliates, or agree to any other structural or conduct remedy (including any conduct of business arrangements or termination of any existing relationships or contractual rights and obligations), or (ii) otherwise take or commit to take any actions that would limit Nordson’s, Atrion’s or any of their respective affiliates’ freedom of action with respect to, or its or their ability to retain any assets, properties, products, rights, services or businesses. The obligation of each party to consummate the Merger is also conditioned upon (a) the accuracy of the representations and warranties of the other party as of the date of the Merger Agreement and as of the Closing (subject to customary materiality qualifiers), (b) compliance by the other party in all material respects with its pre-Closing obligations and covenants under the Merger Agreement, (c) in Nordson’s case, the absence of a material adverse effect with respect to Issuer, and (d) the receipt from the other party of a certificate, signed by an duly authorized officer of such party, certifying as to the satisfaction of certain conditions.

    Under the Merger Agreement, Issuer is subject to customary “no-shop” restrictions on Issuer’s ability to solicit or knowingly encourage or facilitate any alternative acquisition proposals with, execute or enter into any alternative acquisition proposals with, furnish non-public information to, and participate in discussions or negotiations regarding any alternative acquisition proposals with, any third parties, subject to a customary “fiduciary out” provision that allows Issuer, under certain specified circumstances, to furnish information to, and participate in discussions or negotiations with, third parties with respect to a bona fide alternative acquisition proposal from such third parties if (i) Issuer’s board of directors (x) determines in good faith (after consultation with Issuer’s outside legal counsel and outside financial advisor) that such alternative acquisition proposal is, or would reasonably be likely to lead to, a Superior Proposal, and (y) determines in good faith (after consultation with its


    outside legal counsel) that its failure to take such actions would be reasonably likely to be inconsistent with its fiduciary duties under applicable law, and (ii) Issuer provides written notice to Nordson of such determination promptly (and in any event within twenty-four hours of such determination) and (iii) Issuer receives or has received from such third party an executed acceptable confidentiality agreement. Under the Merger Agreement, Issuer is also required to pay a termination fee of $20 million to Nordson if the Merger Agreement is terminated (a) by Issuer, prior to obtaining the Issuer Stockholder Approval, in order to enter into a definitive agreement with respect to a Superior Proposal, (b) by Nordson if Issuer’s board of directors effects an adverse recommendation change prior to obtaining the Issuer Stockholder Approval, (c) in certain circumstances, by either Nordson or Issuer if the Effective Time has not occurred on the Outside Date (as defined below) or if the Issuer Stockholder Approval is not obtained, or (d) by Nordson if Issuer breaches its representations, warranties or covenants in a manner that would result in a failure of an applicable closing condition to be satisfied and, if curable, Issuer fails to cure such breach within the applicable time period specified in the Merger Agreement and, in each case of the foregoing clauses (c) and (d), if (i) at or prior to the date of such termination, an alternative acquisition proposal has been publicly announced, disclosed or otherwise made public, remains outstanding and is not publicly withdrawn within a specified period of time, and (ii) within twelve (12) months of the termination date, Issuer or any of its subsidiaries consummates an alternative acquisition proposal or enters into a definitive agreement with respect to an alternative acquisition proposal or an alternative acquisition proposal is submitted to the stockholders of Issuer or its subsidiaries for adoption.

    The Merger Agreement contains certain customary termination rights for Issuer and Nordson, including the right of (i) either party to terminate the Merger Agreement if the Effective Time has not occurred by 5:00 p.m., New York time, on February 28, 2025 (as it may be extended to August 28, 2025 pursuant to the terms of the Merger Agreement, the “Outside Date”), (ii) Nordson to terminate the Merger Agreement if Issuer’s board of directors effects an adverse recommendation change prior to obtaining the Issuer Stockholder Approval, (iii) either party to terminate the Merger Agreement if the other party breaches its representations, warranties or covenants in a manner that would cause the related conditions to the closing set forth in the Merger Agreement to not be satisfied and such other party fails to timely cure such breach, (iv) either party to terminate the Merger Agreement if any legal restraint prohibiting the consummation of the Merger has become final and nonappealable, and (v) either party to terminate the Merger Agreement if the Issuer Stockholder Approval is not obtained.

    Nordson will be obligated to pay to Issuer a one-time fee equal to $40,725,000 in cash, if the Merger Agreement is terminated by either party because (i) the Merger has not been consummated by the Outside Date, or (ii) any governmental authority of competent jurisdiction has enacted or promulgated any nonappealable antitrust law or foreign investment law or order (related to the HSR Act or the Required Approvals) permanently enjoining, prohibiting or making illegal the consummation of the Merger, or because any antitrust or foreign investment law (related to the HSR Act or the Required Approvals) is adopted following the execution of the Merger Agreement that makes consummation of the Merger illegal or otherwise prohibited and, in each case of clauses (i) and (ii), at the time of such termination, (1) the conditions to closing relating to the absence of any law or order (relating to the HSR Act or the Required Approvals) enjoining or otherwise making illegal the consummation of the Merger, the expiration of the applicable waiting period under the HSR Act, or the receipt of the Required Approvals have not been satisfied or waived (or have been satisfied only with the imposition of a Burdensome Condition), and (2) the other conditions to closing in favor of Nordson have been satisfied or waived (or in the case of conditions that by their terms are to be satisfied at the closing, are capable of being satisfied if the closing were to occur on such date).

    Issuer has made customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants (i) to use reasonable best efforts to conduct the businesses of Issuer and its subsidiaries in the ordinary course of business consistent with past practice during the period between the execution of the Merger Agreement and the Effective Time, and (ii) not to engage in specified types of transactions and not to take specified actions during this period unless consented to in writing by Nordson (such consent not to be unreasonably withheld, conditioned or delayed).

    If the Merger is consummated, the Common Stock will be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the Effective Time.


    At the Effective Time, the directors of Merger Sub immediately prior to the Effective Time will be the directors of the surviving corporation until their respective successors are duly elected or appointed and qualified or until their earlier death, resignation or removal in accordance with the certificate of incorporation and bylaws of the surviving corporation. The officers of Merger Sub immediately prior to the Effective Time will be the officers of the surviving corporation until their respective successors are duly appointed and qualified or until their earlier death, resignation or removal in accordance with the certificate of incorporation and bylaws of the surviving corporation. The directors of Merger Sub are identified on Annex A.

    At the Effective Time, Issuer’s certificate of incorporation will be amended and restated in its entirety to read the same as the certificate of incorporation set forth on Exhibit B of the Merger Agreement and as so amended and restated will be the certificate of incorporation of the surviving corporation, until thereafter amended. At the Effective Time, Issuer’s bylaws will be amended and restated to be substantially identical to the bylaws of Merger Sub as in effect immediately prior to the Effective Time (except that the name of the Merger Sub will be replaced by reference to the name of the surviving corporation) and as so amended and restated will be the bylaws of the surviving corporation, until thereafter amended.

    Voting Agreements

    In connection with the execution of the Merger Agreement, Nordson entered into Voting and Support Agreements (the “Voting Agreements”) with the Voting Parties. The Voting Agreements provide that, among other things, the Voting Parties will vote the shares of Common Stock set forth opposite such Voting Party’s name on Schedule A to the applicable Voting Agreement (together with any additional shares of Common Stock or voting securities acquired by such Voting Party after the date of the Voting Agreement, the “Subject Shares”), (i) in favor of the approval and adoption of the Merger Agreement and any actions related thereto, (ii) in favor of any proposal to adjourn a meeting of the stockholders of Issuer to solicit additional proxies in favor of the approval and adoption of the Merger Agreement and any actions related thereto, and (iii) against any (1) alternative acquisition proposal, (2) reorganization, recapitalization, liquidation or winding-up of Issuer or any other extraordinary transaction involving Issuer, (3) action or agreement the consummation of which would reasonably be expected to prevent or delay the consummation of the Merger, (4) action or agreement that would reasonably be expected to result in a material breach or violation of any covenant, representation or warranty or any other obligation of such Voting Party contained in the Voting Agreements, or (5) change in the membership of Issuer’s board of directors, unless approved by Nordson.

    In the aggregate, the Voting Agreements obligate the Voting Parties to vote approximately 22% of the outstanding shares of Common Stock in favor of adoption of the Merger Agreement, based on 1,759,954 shares of Common Stock outstanding as of May 23, 2024, as reported by Issuer in the Merger Agreement (as defined below), which is attached hereto as Exhibit 99.1. Each Voting Party has also agreed in the Voting Agreements to certain restrictions on the transfer of its shares of Common Stock, subject to the terms and conditions set forth in such Voting Party’s Voting Agreement.

    The Voting Agreements provide that they will automatically terminate upon the earliest to occur of (i) the Effective Time, (ii) the termination of the Merger Agreement in accordance with its terms, (iii) as to any Voting Party, any amendment to the Merger Agreement that reduces the amount of or changes the form of, or imposes any material restrictions or conditions on the payment of, the Merger Consideration or extends the Outside Date, in each case, unless such the applicable Voting Party has consented to such amendment, or (iv) the mutual written agreement of the parties to the applicable Voting Agreement.

    The number of shares of Common Stock that the Reporting Person may be deemed to beneficially own as a result of the Voting and Support Agreements is 386,910.

    The foregoing descriptions of the Merger Agreement and the Voting Agreements do not purport to be complete and are qualified in their entirety by reference to such agreements. The Merger Agreement, the Voting Agreements with certain shareholders named on Annex B hereto and the form of Voting Agreements with each of the parties to the Voting Agreements are referenced herein as Exhibits 1, 2 and 3, respectively, and are incorporated by reference into this Item 4.


    Nordson required that the Voting Parties agree to enter into the Voting Agreements as a condition to Nordson’s and Merger Sub’s willingness to enter into the Merger Agreement and to consummate the transactions contemplated by the Merger Agreement, including the Merger.

    During the pendency of the transactions contemplated by the Merger Agreement, the Reporting Person may take actions to comply with the Reporting Person’s obligations, and to enforce the rights of the Reporting Person, under the Merger Agreement.

    Except as set forth in or incorporated by reference in this Schedule 13D, the Reporting Person has no plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

    Item 5. Interest in Securities of Issuer

    The responses of the Reporting Person to rows (7) through (13) of the cover page to this Schedule 13D and Items 2, 3, 4 and 6 are incorporated by reference in this Item 5 as if fully set forth herein.

    (a)-(b) Other than those shares of Common Stock that may be deemed to be beneficially owned by the Reporting Person by virtue of the Voting Agreements, the Reporting Person has not acquired and does not beneficially own any shares of Common Stock. The Reporting Person is not entitled to any rights as shareholders of Issuer as to the shares of Common Stock covered by the Voting Agreements, except as expressly provided in the Voting Agreements. This Schedule 13D will not be construed as an admission by the Reporting Person that such person is, for the purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act, the beneficial owner of any shares of Common Stock.

    Except as set forth in this Schedule 13D, neither the Reporting Person nor, to the best of the knowledge of the Reporting Person, any of the persons listed in Annex A beneficially own any shares of Common Stock or have any right to acquire any shares of Common Stock.

    Set forth on Annex B to this Schedule 13D, and incorporated herein by reference, is, to the best of the knowledge of the Reporting Person, the information required by Item 2 of Schedule 13D for each of the Voting Parties with whom the Reporting Person may be deemed to have shared voting power with respect to the shares of Common Stock beneficially owned by such Voting Parties. However, the Reporting Person (i) is not entitled to any rights as a shareholder of Issuer as to the Subject Shares, except as otherwise expressly provided in the Voting Agreements, and (ii) neither the filing of this Schedule 13D nor any of its content will be deemed to constitute an admission that the Reporting Person is the beneficial owner of any of the Common Stock referred to herein for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act.

    The Reporting Person hereby disclaims that it constitutes a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with the Voting Parties.

    (c) Neither the Reporting Person nor, to the best of the knowledge of the Reporting Person, any of the persons listed in Annex A, has effected any transactions in the shares of Common Stock during the past sixty days.

    (d) Except with reference to the Merger Agreement and the Voting Agreements and the transactions contemplated by those agreements, and except as set forth in this Schedule 13D, to the best of the knowledge of the Reporting Person, no person (other than the Voting Parties) has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock.

    (e) Not applicable.


    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of Issuer

    The information set forth under Items 3, 4 and 5 and the agreements set forth on the Exhibits attached hereto are incorporated by reference in this Item 6.

    Except as set forth in this Schedule 13D, to the best of the knowledge of the Reporting Person, there are no contracts, arrangements, understandings or relationships (legal or otherwise), among the Reporting Person or any of the persons listed in Annex A, or between such persons and any other person, with respect to any securities of Issuer (including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements), including, but not limited to, transfer or voting of any of the shares of Common Stock, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

    Item 7. Material to be Filed as Exhibits

     

    Exhibit
    No.
       Description
    1    Agreement and Plan of Merger, dated as of May 28, 2024, by and among Nordson Corporation, Alpha Medical Merger Sub, Inc., and Atrion Corporation.
    2    Voting and Support Agreement, dated as of May 28, 2024, by and among Nordson Corporation, Montclair Harbour LLC, David A. Battat and Emile A. Battat.
    3    Voting and Support Agreement, dated as of May 28, 2024, by and among Nordson Corporation, Stupp Bros., Inc. and John P. Stupp Jr.
    4    Form of Voting and Support Agreement.


    SIGNATURES

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    Date: May 30, 2024

     

    NORDSON CORPORATION
    By:  

    /s/ Jennifer McDonough

      Name:   Jennifer McDonough
      Title:   Executive Vice President, General Counsel and Secretary


    Annex A

    Information Concerning Executive Officers and

    Directors of Nordson Corporation

    Set forth below are the name and present principal occupation of each director and executive officer of Nordson Corporation as of the date hereof. Unless otherwise indicated, (x) the executive officer’s or director’s business address is located at 28601 Clemens Road Westlake, OH 44145, (y) the name, principal business and address of the corporation or other organization in which an executive officer’s or director’s employment is conducted refers to Nordson Corporation as described in the response to Item 2 of this Schedule 13D, which is incorporated herein by reference, and (z) unless otherwise indicated, the persons listed below are citizens of the United States of America.

     

    Name     

      

    Present Principal Occupation & Principal Business Address

    Executive Officers

        
    Sundaram Nagarajan    President and Chief Executive Officer
    Daniel Hopgood    Executive Vice President and Chief Financial Officer
    James E. DeVries    Executive Vice President
    Stephen P. Lovass    Executive Vice President
    Jennifer L. McDonough    Executive Vice President, General Counsel and Secretary
    Joseph P. Kelley    Executive Vice President
    Sarah Siddiqui    Executive Vice President and Chief Human Resources Officer
    Srini Subramanian    Executive Vice President

    Board of Directors

        
    Michael J. Merriman, Jr.    Business Consultant, Product Launch Ventures, LLC
    John DeFord    Chairman, Chief Executive Officer and President, Samothrace Medical Innovations, Inc.
    Frank M. Jaehnert    Retired President and Chief Executive Officer, Brady Corporation
    Ginger M. Jones    Retired Sr. Vice President and Chief Financial Officer, Cooper Tire & Rubber Company
    Dr. Milton Morris    Principal, MEHL BioMedical, LLC
    Jennifer Parmentier    Chief Executive Officer, Parker Hannifin Corporation
    Victor L. Richey, Jr.    Chairman, Retired President and Chief Executive Officer, ESCO Technologies, Inc.

    Christopher L. Mapes

     

    Sundaram Nagarajan

      

    Executive Chairman, Retired President and Chief Executive Officer, Lincoln Electric Holdings, Inc.

     

    President and Chief Executive Officer, Nordson Corporation

    Annette Clayton    Chairwoman, Former President and Chief Executive Officer Schneider Electric North America


    Annex B

     

    Name of Voting Party

       Subject Shares  

    Emile A. Battat (1)

         150,616  

    David A. Battat (2)

         39,400  

    Montclair Harbour LLC

         55,500  

    John P. Stupp Jr. (3)

         6,394  

    Stupp Bros., Inc.

         135,000  

     

    (1)

    Mr. Emile A. Battat also directly beneficially owns certain restricted stock units of Issuer that are to be settled in cash.

     

    (2)

    David A. Battat has shared voting and investment power over the 55,500 shares of Common Stock held by Montclair Harbour LLC and listed in this Annex B. Mr. David A. Battat also directly beneficially owns certain restricted stock units of Issuer that are to be settled in cash.

     

    (3)

    Mr. John P. Stupp, Jr. has voting power and investment power over the 135,000 shares of Common Stock held by Stupp Bros., Inc. and listed in this Annex B, as the as a Chairman, President and Chief Executive Officer of such entity. The 135,000 shares of Common Stock held by Stupp Bros., Inc. are pledged to certain lenders of Stupp Bros., Inc. as security for its working capital line of credit. In addition, Mr. John P. Stupp, Jr. is the direct beneficial owner of (i) 6,394 shares of Common Stock which are pledged as collateral for a mortgage loan, and (ii) 561.22 restricted stock units held in Mr. John P. Stupp, Jr.’s restricted stock unit account that have not been converted into shares of Common Stock as of the date hereof. A family trust, the co-trustees of which are Mr. John P. Stupp, Jr.’s wife and one of his children, also directly beneficially owns 22,330 shares of Common Stock.


    Exhibit Index

     

    Exhibit
    No.
       Description
    1    Agreement and Plan of Merger, dated as of May 28, 2024, by and among Nordson Corporation, Alpha Medical Merger Sub, Inc. and Atrion Corporation.
    2    Voting and Support Agreement, dated as of May 28, 2024, by and among Nordson Corporation and the Stockholders party thereto.
    3    Voting and Support Agreement, dated as of May 28, 2024, by and among Nordson Corporation and the Stockholders party thereto.
    4    Form of Voting and Support Agreement.
    Get the next $ATRI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATRI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stupp John P Jr returned $69,149,960 worth of shares to the company (150,326 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 5:00:44 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Spaulding Ronald Nicholas returned $1,231,880 worth of shares to the company (2,678 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:30:30 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Athey Preston G returned $629,280 worth of shares to the company (1,368 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:19:38 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Athey Preston G bought $95,904 worth of shares (300 units at $319.68), increasing direct ownership by 28% to 1,368 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      12/1/23 2:53:55 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Battat David A bought $90,000 worth of shares (300 units at $300.00), increasing direct ownership by 0.77% to 39,400 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      11/16/23 2:49:33 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Atrion Corporation

      15-12G - ATRION CORP (0000701288) (Filer)

      9/3/24 9:11:57 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:24:19 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:23:12 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Atrion Corporation Enters Into Merger Agreement with Nordson Corporation

      ALLEN, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million. The transaction enterprise value reflects a multiple of 20.2 times Atrion's 2023 EBITDA, and the $460 per share price represents a 15% premium to Atrion's 90-day average daily volume-weighted average stock price. The proposed transaction was unanimously approved by the Boards of Directors of Atrion

      5/28/24 7:24:38 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials

    $ATRI
    Financials

    Live finance-specific insights

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials
    • Atrion Corporation Declares Quarterly Cash Dividend

      ALLEN, Texas, May 21, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy FergusonVice President and Chief Financial Officer(972) 390-9800         

      5/21/24 4:30:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atrion Corporation

      SC 13G/A - ATRION CORP (0000701288) (Subject)

      9/9/24 4:05:03 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:05:08 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:04:56 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care